Center for Cancer and Blood Disorders Launches CAR T-Cell Therapy Program in Maryland, Expanding Community Access

Key Takeaways

• Center for Cancer and Blood Disorders receives FDA authorization to administer CAR T-cell therapy at community oncology clinic
• First patient treatment marks significant expansion of advanced cancer therapy access in Maryland, D.C., and Northern Virginia
• Program eliminates need for patients to travel to major academic medical centers for cutting-edge immunotherapy treatment

---

BETHESDA, Md. — The Center for Cancer and Blood Disorders (CCBD) has received FDA authorization to administer chimeric antigen receptor (CAR) T-cell therapy, marking a significant milestone in community-based cancer care accessibility in the Maryland region.

The oncologist-led program, launched through CCBD’s partnership with American Oncology Network (AON), represents the first community oncology practice in Maryland to offer this advanced immunotherapy treatment. The initiative serves patients across Maryland, Washington D.C., and Northern Virginia.

Expanding Access to Advanced Cancer Treatment

CAR T-cell therapy represents a breakthrough in cancer immunotherapy, genetically modifying patients’ T-cells to better recognize and attack cancer cells. Previously, patients requiring this treatment typically needed to travel to major academic medical centers, creating barriers to access.

“This program brings cutting-edge cancer treatment directly to our community,” said CCBD officials. The authorization allows the practice to treat patients with various blood cancers, including certain types of lymphoma and leukemia.

IntelligenceRegulatory Impact▾

FDA are the agencies to watch. Regulatory relevance reads medium for pharmaceutical intelligence. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

Market Impact and Patient Benefits

The expansion of CAR T-cell therapy into community settings reflects a broader trend in oncology care delivery. By offering these treatments locally, CCBD eliminates travel burdens and reduces treatment delays for eligible patients.

American Oncology Network, one of the nation’s fastest-growing community oncology networks, continues expanding access to advanced therapies through its partner practices. This model demonstrates how community oncology can deliver sophisticated treatments traditionally available only at academic centers.

IntelligenceCompetitive Intelligence▾

Competitive pressure is low. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.

Treatment Availability and Next Steps

CCBD has already begun treating its first community oncology patient under the new program. The practice expects to gradually increase patient capacity as the program establishes operational protocols and staff training.

The FDA-approved CAR T-cell therapies available through CCBD target specific cancer types, with treatment eligibility determined through comprehensive patient evaluation and multidisciplinary team review.

---

Frequently Asked Questions

What types of cancer can be treated with CAR T-cell therapy at CCBD?

CCBD offers FDA-approved CAR T-cell therapies primarily for blood cancers, including certain types of lymphoma and leukemia. Specific eligibility depends on individual patient factors and disease characteristics.

How does receiving CAR T-cell therapy at a community practice differ from academic centers?

Community-based CAR T-cell therapy offers the same FDA-approved treatments with the convenience of local access, reducing travel requirements while maintaining the same safety and efficacy standards as academic medical centers.

When will CAR T-cell therapy be fully available to new patients at CCBD?

CCBD has already begun treating patients and expects to gradually expand capacity. Interested patients should consult with their oncologist to determine eligibility and discuss treatment timing.

Related coverage

• European Cancer Guidelines Add Delcath Liver Therapy for Eye Melanoma
• Cancer Therapy OST-HER2 Faces 2026 EMA Call After Survival Data
• FDA Voucher Program Pause Urged: Rare Disease Policy Analysis